SCHEMBL4745880

SCHEMBL4745880

Cc1ccc2c(c1)c(-c1ccc3c4c(cccc14)-c1ccccc1-3)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
PABPC1 P11940 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
HTT P42858 1/20 0.32
RECQL P46063 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
CRHBP P24387 1/20 0.31
CRHR2 Q13324 1/20 0.31
KEAP1 Q14145 1/20 0.31
NFE2L2 Q16236 1/20 0.31
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30
CASP1 P29466 1/20 0.30
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4745982 0.96 ALDH1A1 (0.34) MAPTKDM4EPABPC1SMN1; SMN2MEN1
SCHEMBL4746272 0.95 MAPT (0.32) MAPTKDM4EPABPC1SMN1; SMN2MEN1
SCHEMBL4746409 0.94 PDK2 (0.33) MAPTKDM4ESMN1; SMN2MEN1USP2
SCHEMBL4746394 0.93 MEN1 (0.32) MAPTKDM4ESMN1; SMN2MEN1USP2
SCHEMBL4745981 0.93 ALDH1A1 (0.33) MAPTKDM4EPABPC1SMN1; SMN2MEN1
SCHEMBL4745860 0.90 MAOA (0.35) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL4745895 0.90 BCHE (0.33) BCHE
SCHEMBL4745985 0.90 BCHE (0.33) ALDH1A1PDK2TOP2ABCHE
SCHEMBL4746466 0.89 TOP2A (0.32) MAPTKDM4ESMN1; SMN2MEN1HTT
SCHEMBL4745943 0.89 ALDH1A1 (0.33) ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 MAPT 1861/4885KDM4E 219/4885PABPC1 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.